	US 12,138,295 B2
	Methods of treating Crohn's disease with anti-IL23 specific antibody
Omoniyi Adedokun, Phoenixville, PA (US); Daphne Chan, Abington, PA (US); Yang Chen, Ambler, PA (US); and Philippe Szapary, Wynnewood, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Mar. 25, 2021, as Appl. No. 17/212,424.
Application 17/212,424 is a continuation of application No. 16/291,310, filed on Mar. 4, 2019, abandoned.
Claims priority of provisional application 62/638,624, filed on Mar. 5, 2018.
Prior Publication US 2021/0308220 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 1/00 (2006.01); A61P 37/06 (2006.01); C07K 16/24 (2006.01)

CPC A61K 38/1793 (2013.01) [A61P 1/00 (2018.01); A61P 37/06 (2018.01); C07K 16/244 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); C07K 2317/76 (2013.01)]

15 Claims

1. A method of treating Crohn's disease in a patient, comprising administering an antibody to IL-23 to the patient, wherein the antibody comprises a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;

a CDRL2 amino acid sequence of SEQ ID NO:56; and

a CDRL3 amino acid sequence of SEQ ID NO:73,

said heavy chain variable region comprising:

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5;

a CDRH2 amino acid sequence of SEQ ID NO:20; and

a CDRH3 amino acid sequence of SEQ ID NO:44;

and wherein the antibody is administered intravenously in three equal doses of: an initial dose, a second dose 4 weeks after the initial dose, and a third dose 8 weeks after the initial dose and the doses are selected from the group consisting of 200 mg, 600 mg and 1200 mg.